$599

Verdiva Appoints Ex-Metsera Execs; Zealand Initiates New GIP Ph1 Obesity Study; MannKind Furoscix ReadyFlow US Approval; July CHMP Highlights; Evogene Partners for PCSK9i Development

A series of cardiometabolic-related news items has been observed from Verdiva Bio, Zealand Pharma, MannKind, FDA, EMA, and Evogene/ELEO. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here